Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe depression: is there a best approach?

S B Sonawalla1, M Fava

  • 1Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

CNS Drugs
|October 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spine surgery and complication in familial dysautonomia: a case report.

Frontiers in surgery·2025
Same author

Promoting resilience in healthcare workers during the COVID-19 pandemic with a brief online intervention.

Journal of psychiatric research·2021
Same author

A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Molecular psychiatry·2019
Same author

Salience network coupling is linked to both tobacco smoking and symptoms of attention deficit hyperactivity disorder (ADHD).

Drug and alcohol dependence·2017
Same author

Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1].

Journal of affective disorders·2017
Same author

Revisiting the role of the insula and smoking cue-reactivity in relapse: A replication and extension of neuroimaging findings.

Drug and alcohol dependence·2017

Severe depression is assessed by symptoms, functional capacity, and suicidality. Treatment options include various antidepressants, atypical antipsychotics, combination therapies, cognitive behavioral therapy, and electroconvulsive therapy for resistant or severe cases.

Area of Science:

  • Psychiatry and Clinical Psychology
  • Neuroscience
  • Pharmacology

Background:

  • Major depressive episodes are categorized as severe based on multiple factors including symptoms, functional impairment, and suicidality.
  • Biological, psychological, social factors, and comorbidities significantly influence depression severity and treatment outcomes.
  • Untreated severe depression carries risks of suicide, self-harm, and treatment resistance.

Purpose of the Study:

  • To review the classification and influencing factors of severe depression.
  • To explore the efficacy of various pharmacological and non-pharmacological treatment modalities for severe depression.
  • To identify potential complications and indications for advanced treatments like electroconvulsive therapy.

Main Methods:

Related Experiment Videos

  • Literature review of studies on severe depression classification, contributing factors, and treatment outcomes.
  • Analysis of data on the efficacy of antidepressants such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).
  • Evaluation of evidence for combination therapies, cognitive behavior therapy (CBT), atypical antipsychotics, and electroconvulsive therapy (ECT).

    • Main Results:

    • Efficacy data for TCAs versus SSRIs in severe depression are mixed, with some studies showing TCAs as more efficacious and others indicating equivalent efficacy.
    • Newer antidepressants may offer advantages over SSRIs in some cases, though study sample sizes are often small.
    • Combination therapies, including SSRI-TCA and antidepressant-antipsychotic combinations, show promise. Cognitive behavior therapy (CBT) and electroconvulsive therapy (ECT) are indicated for specific severe or resistant depression subtypes.

    Conclusions:

    • Severe depression is a complex condition influenced by numerous factors, requiring tailored treatment approaches.
    • Pharmacological options range from traditional antidepressants to newer agents and combination therapies.
    • Non-pharmacological interventions like CBT and ECT play crucial roles in managing severe, resistant, or medically complicated depression.